GLG News in Healthcare

Doctors must be educated on the correct use of Methadone if unnecessary deaths are to be avoided.

NICE has stated that the cost of several novel agents for the treatment of renal cell cancer including Sutent, Torisel, Avastin, and Nexavar exceeds the benefit when assessed by quality adjusted life years (QALY) gained from the therapies.

The general public hears the bullet that stents are no better than medications, but the reality that this trial (COURAGE trial) had major flaws, the main being that only 10% of the patients screened participated in the trial. 90% were excluded. Thus, the patients enrolled were not necessarily the typical patients. Also, very few of the new, drug-eluting stents were used. That being said, the initial...

If truly an association, this will alter the use of this drug.

Healthways is currently struggling, but hopfully this will only be a temporary local difficulty. In the long run Healthways provides a good service

1.  The phase II clinical trial  of the combination thherapy of ( temozolomide and Thalidomide for Malignant Melanoma is very encourganing. It may open new avenue to treat   malignant melanoma  affecting Brain. 2. This  article is important for use  of combination therapy for other diseases. 3.  May be  other GBM drugs and Thalidomide could be used for...

Children have long been therapeutic orphans, often relying on off-label use of new drugs which have only been tested on adults. This legislation seeks to remedy that inequality, by encouraging pharmaceutical companies to do more testing in pediatric populations.

The new prostaglandin analog is not what i find interesting in this article. A new treatment for Diabetic Retinopathy sounds much more interesting

Healthways reported lower than expected earnings in its current quarter and analysts are pointing to a tightening in the healthcare markets and the fact that Healthways products are expensive. Does this really make sense?

This is the 4th in its class of oral antiemetics to control acute phase CINV.  It is likely to be cost-prohibitive in the company of generical ondansetron.  Palonosetron's control of delayed CINV in the IV formulation makes it the better choice among it's class; therefore, losing this indication in the oral form will make it less attractive to use.